Best Practice & Research Clinical Endocrinology & Metabolism
Volume 21, Issue 1 , Pages 69-85 , March 2007

Nuclear imaging of neuroendocrine tumours

  • Anders Sundin, MD, PhD (Professor)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +46 18 611 00 00.

References 

  1. Tiensuu Jansson E, Öberg K. Malignant neuroendocrine tumors. Cancer Chemotherapy and Biological Response Modifiers. 2002;20:464–470
  2. Rindi G, Capella C, Solcia E. Cell biology, clinicopathological profile, and classification of gastro-enteropancreatic endocrine tumors. Journal of Molecular Medicine. 1998;76:413–420
  3. Patel YC, Amherdt M, Orci L. Quantitative electron microscopic autoradiography of insulin, glucagon and somatostatin binding on islets. Science. 1982;217:1155–1156
  4. Patel YC. Molecular pharmacology of somatostatin receptor subtypes. Journal of Endocrinological Investigation. 1997;20:348–367
  5. Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. European Journal of Nuclear Medicine. 2001;28:836–846
  6. Krenning EP, Bakker WH, Kooij PP, et al. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: Metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. Journal of Nuclear Medicine. 1992;5:652–658
  7. Krenning EP, Bakker WH, Breeman WA, et al. Localization of endocrine-related tumors with radio iodinated analogue of somatostatin. Lancet. 1989;1:242–244
  8. Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with 111In-DTPA-D-Phe1- and 123I-Tyr3-Octreotide: the Rotterdam experience with more than 1,000 patients. European Journal of Nuclear Medicine. 1993;20:716–731
  9. Gibril F, Reynolds JC, Doppman JL, et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. Annals of Internal Medicine. 1996;125:26–34
  10. Lebtahi R, Cadiot G, Sarda L, et al. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. Journal of Nuclear Medicine. 1997;6:853–858
  11. Termanini B, Gibil F, Reynolds JC, et al. Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management. Gastroenterology. 1997;112:335–347
  12. Kwekkeboom DJ, Kooij PP, Bakker WH, et al. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake. Journal of Nuclear Medicine. 1999;40:762–767
  13. Wild D, Macke HR, Waser B, et al. 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. European Journal of Nuclear Medicine and Molecular Imaging. 2005;32:724
  14. Ginj M, Chen J, Walter MA, et al. Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy. Clinical Cancer Research. 2005;11:1136–1145
  15. Hubalewska-Dydejczyk A, Fross-Baron K, Mikolajczak R, et al. (99m)Tc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years' experience. European Journal of Nuclear Medicine and Molecular Imaging. 2006;33:1123–1133
  16. Storch D, Behe M, Walter MA, et al. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?. Journal of Nuclear Medicine. 2005;46:1561–1569
  17. Gabriel M, Decristoforo C, Donnemiller E, et al. An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors. Journal of Nuclear Medicine. 2003;44:708–716
  18. Gabriel M, Decristoforo C, Maina T, et al. 99mTc-N4-[Tyr3]Octreotate Versus 99mTc-EDDA/HYNIC-[Tyr3]Octreotide: an intrapatient comparison of two novel Technetium-99m labeled tracers for somatostatin receptor scintigraphy. Cancer Biotherapy & Radiopharmaceuticals. 2004;19:73–79
  19. Decristoforo C, Maina T, Nock B, et al. 99mTc-Demotate 1: first data in tumour patients-results of a pilot/phase I study. European Journal of Nuclear Medicine and Molecular Imaging. 2003;30:1211–1219
  20. Lebtahi R, Le Cloirec J, Houzard C, et al. Detection of neuroendocrine tumors: 99mTc-P829 scintigraphy compared with 111In-pentetreotide scintigraphy. Journal of Nuclear Medicine. 2002;43:889–895
  21. Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. Journal of Clinical Oncology. 2005;23:2754–2762
  22. Esser JP, Krenning EP, Teunissen JJ, et al. Comparison of [(177)Lu-DOTA (0),Tyr (3)]octreotate and [(177)Lu-DOTA (0),Tyr (3)]octreotide: which peptide is preferable for PRRT?. European Journal of Nuclear Medicine and Molecular Imaging. 2006;33:1346–1351
  23. Kwekkeboom D, Krenning EP, de Jong M. Peptide receptor imaging and therapy. Journal of Nuclear Medicine. 2000;41:1704–1713
  24. Bombardieri E, Aktolun C, Baum RP, et al. 111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. European Journal of Nuclear Medicine and Molecular Imaging. 2003;30:BP140–BP147
  25. Schillaci O, Scopinaro F, Angeletti S, et al. SPECT improves accuracy of somatostatin receptor scintigraphy in abdominal carcinoid tumors. Journal of Nuclear Medicine. 1996;37:1452–1456
  26. Schillaci O, Spanu A, Scopinaro F, et al. Somatostatin receptor scintigraphy in liver metastasis detection from gastroenteropancreatic neuroendocrine tumors. Journal of Nuclear Medicine. 2003;44:359–368
  27. Öberg K, Kvols L, Caplin M, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Annals of Oncology. 2004;15:966–973
  28. Dromain C, de Baere T, Lumbroso J, et al. Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. Journal of Clinical Oncology. 2005;23:70–78
  29. Granberg D, Sundin A, Janson ET, et al. Octreoscan in patients with bronchial carcinoid tumours. Clinical Endocrinology. 2003;59:793–799
  30. de Herder WW, Kwekkeboom DJ, Valkema R, et al. Neuroendocrine tumors and somatostatin: imaging techniques. Journal of Endocrinological Investigation. 2005;28(11 supplement):132–136
  31. Lanberts SWJ, Hofland LJ, van Koetsveld PM, et al. Parellel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: consequences with regards to diagnosis, localization and therapy. The Journal of Clinical Endocrinology and Metabolism. 1990;71:566–574
  32. Janson ET, Westlin JE, Eriksson B, et al. 111In-DTPA-D-Phe1 Octreotide scintigraphy in patients with carcinoid tumors: the predictive value for somatostatin analogue treatment. European Journal of Endocrinology. 1994;131:577–581
  33. Reubi JC, Macke HR, Krenning EP. Candidates for peptide receptor radiotherapy today and in the future. Journal of Nuclear Medicine. 2005;46(supplement 1):67S–75S
  34. Kaltsas G, Korbonits M, Heintz E, et al. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. The Journal of Clinical Endocrinology and Metabolism. 2001;86:895–902
  35. Ezziddin S, Logvinski T, Yong-Hing C, et al. Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors. Journal of Nuclear Medicine. 2006;47:223–233
  36. Mukherjee JJ, Kaltsas GA, Islam N, et al. Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG]. Clinical Endocrinology. 2001;55:47–60
  37. Buscombe JR, Cwikla JB, Caplin ME, Hilson AJ. Long-term efficacy of low activity meta-[131I]iodobenzylguanidine therapy in patients with disseminated neuroendocrine tumours depends on initial response. Nuclear Medicine Communications. 2005;26:969–976
  38. Brogsitter C, Pinkert J, Bredow J, et al. Enhanced tumor uptake in neuroendocrine tumors after intraarterial application of 131I-MIBG. Journal of Nuclear Medicine. 2005;46:2112–2116
  39. Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Seminars in Nuclear Medicine. 2006;36:228–247
  40. Lin WY, Tsai SC, Hung GU. Value of delayed 18F-FDG-PET imaging in the detection of hepatocellular carcinoma. Nuclear Medicine Communications. 2005;26:315–321
  41. von Schulthess GK, Steinert HC, Hany TF. Integrated PET/CT: current applications and future directions. Radiology. 2006;238:405–422
  42. Ell PJ. The contribution of PET/CT to improved patient management. The British Journal of Radiology. 2006;79:32–36
  43. Reske SN, Kotzerke J. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, ‘Onko-PET III’, 21 July and 19 September 2000'. European Journal of Nuclear Medicine. 2001;28:1707–1723
  44. Kapoor V, McCook BM, Torok FS. An introduction to PET-CT imaging. Radiographics. 2004;24:523–543
  45. Gambhir SS, Czernin J, Schwimmer J, et al. A tabulated summary of the FDG PET literature. Journal of Nuclear Medicine. 2001;42(5 supplement):1S–93S
  46. Bunyaviroch T, Coleman RE. PET evaluation of lung cancer. Journal of Nuclear Medicine. 2006;47:451–469
  47. Kim BT, Lee KS, Shim SS, et al. Stage T1 non-small cell lung cancer: preoperative mediastinal nodal staging with integrated FDG PET/CT-A prospective study. Radiology. 2006;241:501–509
  48. Chin BB, Wahl RL. 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of gastrointestinal malignancies. Gut. 2003;52:23–29
  49. Kantorova I, Lipska L, Belohlavek O, et al. Routine 18F-FDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making. Journal of Nuclear Medicine. 2003;44:1784–1788
  50. Esteves FP, Schuster DM, Halkar RK. Gastrointestinal tract malignancies and positron emission tomography: an overview. Seminars in Nuclear Medicine. 2006;36:169–181
  51. Rodriguez M, Ahlström H, Sundin A, et al. [18F] FDG PET in gastric non-Hodgkin's lymphoma. Acta Oncologica (Stockholm, Sweden). 1997;36:577–584
  52. Juweid ME, Cheson BD. Role of positron emission tomography in lymphoma. Journal of Clinical Oncology. 2005;23:4577–4580
  53. Kapoor V, Fukui MB, McCook BM. Role of [18F]FDG PET/CT in the treatment of head and neck cancers: principles, technique, normal distribution, and initial staging. American Journal of Roentgenology. 2005;184:579–587
  54. Belhocine TZ, Scott AM, Even-Sapir E, et al. Role of nuclear medicine in the management of cutaneous malignant melanoma. Journal of Nuclear Medicine. 2006;47:957–967
  55. Bastiaannet E, Oyen WJ, Meijer S, et al. Impact of [18F]fluorodeoxyglucose positron emission tomography on surgical management of melanoma patients. The British Journal of Surgery. 2006;93:243–249
  56. Kumar R, Chauhan A, Jana S, Dadparvar S. Positron emission tomography in gynecological malignancies. Expert Review of Anticancer Therapy. 2006;6:1033–1044
  57. Jarritt PH, Carson KJ, Hounsell AR, Visvikis D. The role of PET/CT scanning in radiotherapy planning. The British Journal of Radiology. 2006;79(Spec No 1):S27–S35
  58. Adams S, Baum R, Rink T, et al. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumors. European Journal of Nuclear Medicine. 1998;25:79–83
  59. Pasquali C, Rubello D, Sperti C, et al. Neuroendocrine tumor imaging: can 18F-fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior?. World Journal of Surgery. 1998;22:588–592
  60. Foidart-Willems J, Depas G, Vivegnis D. Positron emission tomography and radio labeled octreotide scintigraphy in carcinoid tumors. European Journal of Nuclear Medicine. 1995;22:635–638
  61. Jadavar H, Segall GM. False-negative fluorine-18-FDG-PET in metastatic carcinoid. Journal of Nuclear Medicine. 1997;38:1382–1383
  62. Pacak K, Ilias I, Chen CC, et al. The role of [(18)F]fluorodeoxyglucose positron emission tomography and [(111)In]-diethylenetriaminepentaacetate-D-Phe-pentetreotide scintigraphy in the localization of ectopic adrenocorticotropin-secreting tumors causing Cushing's syndrome. The Journal of Clinical Endocrinology and Metabolism. 2004;89:2214–2221
  63. Kumar J, Spring M, Carroll PV, et al. 18Flurodeoxyglucose positron emission tomography in the localization of ectopic ACTH-secreting neuroendocrine tumours. Clinical Endocrinology. 2006;64:371–374
  64. Pearse AG. The APUD concept and hormone production. Clinics in Endocrinology and Metabolism. 1980;9:211–222
  65. Ahlström H, Eriksson B, Bergström M, et al. Pancreatic neuroendocrine tumours: Diagnosis with PET. Radiology. 1995;195:333–337
  66. Hoegerle S, Altehoefer C, Ghanem N, et al. Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors. Radiology. 2001;220:373–380
  67. Becherer A, Szabo M, Karanikas G, et al. Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET. Journal of Nuclear Medicine. 2004;45:1161–1167
  68. Koopmans KP, de Vries EG, Kema IP, et al. Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. The Lancet Oncology. 2006;7:728–734
  69. Montravers F, Grahek D, Kerrou K, et al. Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors?. Journal of Nuclear Medicine. 2006;47:1455–1462
  70. Hoegerle S, Altehoefer C, Ghanem N, et al. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. European Journal of Nuclear Medicine. 2001;28:64–71
  71. Hoegerle S, Nitzsche E, Altehoefer C, et al. Pheochromocytomas: detection with 18F DOPA whole body PET-initial results. Radiology. 2002;222:507–512
  72. Nanni C, Rubello D, Fanti S. 18F-DOPA PET/CT and neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging. 2006;33:509–513
  73. Örlefors H, Sundin A, Ahlström H, et al. Positron Emission Tomography with 5-hydroxytryptophan in Neuroendocrine tumors. Journal of Clinical Oncology. 1998;16:2534–2542
  74. Örlefors H, Sundin A, Lu L, et al. Carbidopa pretreatment improves image interpretation and visualisation of carcinoid tumours with 11C-5-hydroxytryptophan positron emission tomography. European Journal of Nuclear Medicine and Molecular Imaging. 2006;33:60–65
  75. Brown WD, Oakes TR, DeJesus OT, et al. Fluorine-18-fluoro-L-DOPA dosimetry with carbidopa pretreatment. Journal of Nuclear Medicine. 1998;39:1884–1891
  76. Örlefors H, Sundin A, Garske U, et al. Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. The Journal of Clinical Endocrinology and Metabolism. 2005;90:3392–3400
  77. Hofmann M, Maecke H, Borner R, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. European Journal of Nuclear Medicine. 2001;28:1751–1757
  78. Kowalski J, Henze M, Schuhmacher J, et al. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Molecular Imaging and Biology. 2003;5:42–48
  79. Koukouraki S, Strauss LG, Georgoulias V, et al. Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. European Journal of Nuclear Medicine and Molecular Imaging. 2006;33:460–466
  80. Win Z, Rahman L, Murrell J, et al. The possible role of 68Ga-DOTATATE PET in malignant abdominal paraganglioma. European Journal of Nuclear Medicine and Molecular Imaging. 2006;33:506

PII: S1521-690X(06)00112-6

doi: 10.1016/j.beem.2006.12.003

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 21, Issue 1 , Pages 69-85 , March 2007

Article Tools

* Image Usage & Resolution